Johnson & Johnson Reports Lower Mortality in Impella-Supported PCI Analyses
Johnson & Johnson reports lower mortality in analyses of Impella-supported high-risk PCI versus CHIP-BCIS3.
Story updates
01:00:45 PM UTC
SquawkNews
Johnson & Johnson reported three analyses showing lower in-hospital and 30-/90-day mortality for Impella-supported HRPCI patients in real-world U.S./EU data versus CHIP-BCIS3. PROTECT IV RCT readout is anticipated in 2027.Material DetailsContext by AI AnalystThis is mid-cycle evidence-building, rei…